Incb050465
WebParsaclisib (INCB050465, IBI376) Hydrochloride is a potent and highly selective PI3Kδ (PI3K delta) inhibitor with an IC50 of 1 nM at 1 mM ATP in biochemical assay and approximately 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases. CAS No. 1995889-48-9 Purity & Quality Control Biological Activity Protocol (from reference) WebConclusion INCB050465 administration ameliorated germinal center formation, inhibited salivary gland inflammation and reduced autoantibody titers as a single agent in a dose-dependent manner. Together, the data suggest that INCB050465, a selective PI3Kδ inhibitor, may have potential as a therapeutic agent for the treatment of Sjögren’s ...
Incb050465
Did you know?
Web本文提供了使用磷酸肌醇‑3‑激酶(PI3K)抑制剂治疗癌症的方法。在某些实施方案中，该癌症是滤泡性淋巴瘤(FL)。在某些实施方案中，按连续给药时间表(CS)施用所述PI3K抑制剂。在其他实施方案中，按间歇给药时间表(IS)施用所述PI3K抑制剂。 WebDec 2, 2016 · INCB050465 is a novel, potent, and highly specific inhibitor of PI3Kd (≥19,000-fold more selective for the d vs other isoforms) with no hepatotoxicity in preclinical evaluation at clinically relevant exposures. Here we report the emerging safety, pharmacokinetics, and efficacy results of INCB050465 monotherapy in B-cell malignancies.
WebEssais cliniques sur primary sjogren syndrome. Registre des essais cliniques. ICH GCP. WebDec 2, 2016 · INCB050465 is a novel, potent, and highly specific inhibitor of PI3Kd (≥19,000-fold more selective for the d vs other isoforms) with no hepatotoxicity in preclinical evaluation at clinically relevant exposures. Here we report the emerging safety, pharmacokinetics, and efficacy results of INCB050465 monotherapy in B-cell malignancies.
WebFeb 6, 2024 · INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) The … WebParsaclisib (INCB050465, INCB-50465, IBI376) is a potent and highly selective PI3Kδ (PI3K delta) inhibitor with an IC50 of 1 nM at 1 mM ATP in biochemical assay and approximately …
WebJul 15, 2016 · INCB050465 is a novel, potent, and selective PI3Kδ inhibitor (Shin et al. AACR 2015. Abstract 2671), with a differentiated profile for potency (whole blood IC50 = 10 nM), dose (<50 mg total daily dose), and preclinical safety (lack of hepatoxicity up to exposures that exceed IC90 coverage by >10-fold).
WebINCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ) ACS Medicinal Chemistry Letters RETURN TO ISSUE PREV Letter NEXT … chuqqah in hebrewWebParsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC 50 of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be … chup where to watchWebParsaclisib (INCB050465, IBI376) Hydrochloride is a potent and highly selective PI3Kδ (PI3K delta) inhibitor with an IC50 of 1 nM at 1 mM ATP in biochemical assay and approximately … chuqualatague doubleheadWebNov 4, 2024 · The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are … chur 16 tage wetterWebJul 1, 2024 · Parsaclisib (INCB050465) is a potent and selective next-generation PI3K δ inhibitor that differs in structure from first-generation PI3K δ inhibitors and has shown encouraging anti–B-cell tumor activity and reduced hepatotoxicity in … deterministic safety analysischup wool socksWebJul 1, 2024 · INCB050465 is a potent inhibitor of PI3Kδ, with a >20,000 fold selectivity over other PI3K isoforms. Emerging clinical data indicate that INCB050465 monotherapy is well tolerated and results in promising clinical responses in patients with various lymphoma histologies, including those with DLBCL. deterministic schedule risk analysis